Why Builder D.R. Horton Shares Are Surging Today
D.R. Horton, Inc. reported Q2 FY24 earnings above estimates with sales and orders increasing. Company updates revenue outlook and declares dividend.
FDA Classifies Boston Scientific’s Recall For Device To Stop Blood Flow As ‘Most Serious’
Boston Scientific announces a Class I recall of Obsidio Embolic due to high-risk implications for lower GI bleeding embolization. Potential adverse effects include bowel ischemia, necessitating major surgery or resulting in prolonged hospitalization.
Elevance Health Clocks $2.2B Q1 Net Profit Despite 21% Drop In Medicaid Enrollment, Lifts Annual Guidance
Elevance Health reports Q1 revenues at $42.3 billion, surpassing expectations. CEO Gail Boudreaux highlights strategic growth initiatives, with profit up 12.2% Y/Y and adjusted EPS at $10.64. Medicaid membership decline offset by commercial and ACA enrollment.
Tesla’s Autonomous Driving Efforts Win Praise From Goldman Sachs: Wall Street Firm Projects Long-Term Growth From Robotaxi Services
Goldman Sachs recognizes Tesla's potential for growth in autonomy and ADAS. Delaney notes challenges but sets $175 target, potential $220-$300 upside and $55-$75 downside.
Why Is Alternative Investment Giant Blackstone Stock Falling Premarket Thursday?
Blackstone Inc (NYSE: BX) reported lower Q1 FY24 results with adjusted revenues of $2.55B, beating consensus. Distributable earnings rose 1% and AUM increased by 7%.
Stellantis Charges Up With $100M Solar Investment in Argentina: Report
Stellantis reportedly plans to acquire 49.5% of 360 Energy Solar for $100 million in Argentina to increase renewable energy at its plants, including powering them with 360's solar power plant.
Oracle Bets Big On Japan’s Cloud Boom With $8B Investment
Oracle Corp. (NYSE: ORCL) plans to invest $8B in Japan for cloud computing & AI infrastructure, supporting customers' digital sovereignty needs.
Analysts Raises Forecasts On UnitedHealth On Controlled Growth Strategy After Cyber Hack
UnitedHealth reports robust Q1 results despite cybersecurity challenges. Revenue exceeds $99.8 billion, with adjusted EPS of $6.91, surpassing expectations. Analysts upbeat, Piper Sandler raises price target to $571, while Truist maintains Buy with $600 target.
Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
Johnson & Johnson reports first-quarter earnings, with adjusted EPS up 12.4% and sales up 2.3%. Analysts optimistic about stock's future, highlighting potential growth from new drug approvals. JNJ aims to lead in Innovative Medicines and MedTech.
Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions
Be cautious of counterfeit Botox for cosmetic use. FDA warns of adverse reactions in multiple states. Symptoms include vision issues, difficulty breathing, and weakness. Ensure authenticity before use.